Showing results (1041-1050 of 1,984) with videos related to

Sort By:
Pageof 199
The Lancet. Neurology|February 22, 2025
Autoinflammatory encephalopathy due to PTPN1 haploinsufficiency: a case seriesGaofeng Zhu, Blaise Didry-Barca, Luis Seabra, et al.
The Lancet. Neurology|February 16, 2025
Safety and efficacy of nerinetide in patients with acute ischaemic stroke enrolled in the early window: a post-hoc meta-analysis of individual patient data from three randomised trialsMichael Tymianski, Michael D Hill, Mayank Goyal, et al.
The Lancet. Neurology|November 15, 2025
Lifetime and 10-year absolute risk of cognitive impairment in relation to amyloid PET severity: a retrospective, longitudinal cohort studyClifford R Jack, Mingzhao Hu, Heather J Wiste, et al.
The Lancet. Neurology|September 27, 2025
Blood and CSF biomarkers for multiple sclerosis: emerging clinical applicationsTanuja Chitnis, Roberta Magliozzi, Ahmed Abdelhak, et al.
The Lancet. Neurology|December 28, 2020
Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trialMichael G Fehlings, Jetan H Badhiwala, Henry Ahn, et al.
The Lancet. Neurology|December 14, 2019
Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (BEST): an open-label, randomised controlled trialXinfeng Liu, Qiliang Dai, Ruidong Ye, et al.
The Lancet. Neurology|December 8, 2019
Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort studyKatrina M Moore, Jennifer Nicholas, Murray Grossman, et al.
The Lancet. Neurology|December 10, 2019
The global burden of neurological disorders: translating evidence into policyValery L Feigin, Theo Vos, Emma Nichols, et al.
The Lancet. Neurology|March 22, 2020
Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trialMasayuki Tahara, Tomoko Oeda, Kazumasa Okada, et al.
The Lancet. Neurology|June 18, 2022
Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trialMessoud Ashina, Michel Lanteri-Minet, Patricia Pozo-Rosich, et al.
Pageof 199